Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cancer that primarily affects the elderly, Caucasians, and the immunocompromised. We present a rare case of an immunocompetent young Iranian (non-Caucasian) female with a small nodule on her left arm. The lesion was initially misdiagnosed as an infected cyst and was treated with antibiotics for 20 days before being surgically removed. Unfortunately, the lump regrew rapidly 2 weeks later, when she had a biopsy, which revealed stage III MCC. She was then treated with adjuvant chemoradiotherapy after a thorough surgical resection of the tumor. Despite the fact that she was in remission after completing chemotherapy courses, she developed neutropenic fever, sepsis and died from septic shock. This case emphasizes the necessity of early clinical diagnosis of MCC and obtaining a biopsy with histopathologic evaluation of rapidly evolving skin lesions suggestive of malignancy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366346 | PMC |
http://dx.doi.org/10.1002/ccr3.7587 | DOI Listing |
Cancers (Basel)
February 2025
Department of Plastic, Reconstructive and Aesthetic Surgery, Hand Surgery, Fachklinik Hornheide, 48157 Munster, Germany.
Background: Merkel cell carcinoma (MCC) is a rare and frequently fatal form of skin cancer. Apart from Programmed Cell Death Protein 1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) signaling, there is a lack of knowledge regarding other immune checkpoint molecules. Recent studies have observed elevated glycoprotein CD200 (also known as OX-2) mRNA expression in in different types of tumors, with CD200R-expressing myeloid cells present in the tumor microenvironment.
View Article and Find Full Text PDFBull Cancer
March 2025
Dermatologie, CHU de Tours, Tours, France; Réseau CARADERM, France.
Merkel cell carcinoma (MCC) is a rare skin cancer that mainly affects the elderly, and whose incidence is increasing. Although the exact origin of this cancer remains uncertain, research in recent years has revealed that MCC develops through two oncogenesis pathways: virally induced by the Merkel polyomavirus (80% of cases) and induced by mutations linked to ultraviolet rays (20% of cases). MCC is an aggressive cancer, with a high mortality rate and limited therapeutic options in advanced stage.
View Article and Find Full Text PDFJ Am Acad Dermatol
March 2025
Fred Hutchinson Cancer Center, Seattle, WA; University of Washington, Seattle, WA. Electronic address:
Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were FDA-approved for advanced MCC in 2017, but their real-world survival impact remains unclear.
Objective: Evaluate whether ICI introduction in the US corresponded with improved survival.
Redox Biol
March 2025
Department of Pathology, Medical University of Vienna, Vienna, Austria; European Research Initiative on ALK-Related Malignancies (ERIA), Cambridge, UK. Electronic address:
Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma affecting children and young adults. About 30% of patients develop therapy resistance therefore new precision medicine drugs are highly warranted. Multiple rounds of structure-activity optimization of Caffeic Acid Phenethyl Ester have resulted in CM14.
View Article and Find Full Text PDFJ Neurol
March 2025
Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Background And Objectives: This study aimed to describe the clinical and prognostic characteristics of antibody-positive paraneoplastic neurological syndrome (PNS) associated with immune checkpoint inhibitors (ICIs).
Methods: We conducted a systematic review of relevant publications in PubMed and Embase from inception to December 2023. Patients with positive anti-neuronal antibodies who had a definite, probable, or possible diagnosis of PNS based on the 2021 PNS-Care Score criteria were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!